Canada markets close in 5 hours 5 minutes

Medicure Inc. (MPH.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
1.0100+0.0100 (+1.00%)
As of 09:45AM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • M
    Michael
    25 Years 66 Million in losses.....but Somehow the CEO is a multi millionaire....when all of his other Public Co. businesses have never made money and all his Pubcos do business with his Private ones. . Does anyone find that interesting?
  • P
    Pim
    Medicure posted a new presentation on its website in the middle of December. At that time the stock price was around C$0.70. I wonder how many investors are aware of the content. The company was very explicit about revenue expectations for the coming years, something they have never done in the past. The sales momentum is now underway, driven by Zypitamag. The product has a potential of C$30 million (as a comparison: sales of Medicure in 2020 were circa C$14 million, Q4 has not been published yet). The figures presented show the following: estimated sales for 2021 of C$18 million, 2022 C$27 million, 2023 $37 million. And not include in the figures are potential revenues of earlier mentioned MC 1; neither the recently acquired Marley Drug is incorporated in the figures as far as I understand. The current market cap. of Medicure is C$19 million. That is low....The shares will move higher in my opinion.
  • A
    Araho
    Volume is encreasing. Management needs to jump in and buy shares on open market.
  • T
    Ted
    Medicure International Inc., it intends to file an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") pertaining to its legacy product Pyridoxal 5′-phosphate ("P5P", also referred to as "MC-1") for the treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase ("PNPO") deficiency. The majority of patients with PNPO deficiency have mutations in the PNPO gene, which is required for the production of normal levels of P5P. In connection with the IND, the Company will proceed with a Phase 3 clinical trial to treat PNPO deficient patients with a daily dose of MC-1.
  • A
    Araho
    Zero volume. Please go private or raise fund and expand.
  • A
    Araho
    I wonder if they may not go private. They did not raise any fund recently and they have money to buy back all shares.
  • A
    Araho
    Raise funds. and develop your business or go private. This is a joke.
  • A
    Araho
    A new era just begins here with an online pharmacy.
  • R
    Richard
    Sell the company payout shareholders what’s left. Best way to get rid of directors.
  • S
    Steve Stevens
    I believe the market cap at Medicure's peak during Apicore acquisition was near $200mm. Currently, it's a quarter of that. I applaud Friessen for what he had done to get shares out of the rut, however, that was over 2 years ago and since then,,,he's been batting zero. That windfall from the Apicore sale is perhaps down to $30mm with the recent drug acquisition. he's trying to build the co. revenue wise with a portfolio of aggrastat-type sales--getting something on the cheap and growing revs. Unfortunately, the recent additions have been misses rather than hits,
  • T
    Ted
    Not a responsive stock. Its going nowhere. I bet and lost on this one.
  • K
    Kevin
    this is a good questions Ted. We can only hope so that we can get back above water with this stock.
  • N
    N
    does this stock ever move? Low to no volume everyday
  • J
    Jim
    Investors buy stock to make money. Share prices rise as earnings per share rise. So when I see a company like this one with quarterly sales growth of over 100 % and zero growth in earnings per share over the prior years quarterly earnings, it informs me that management of this company is doing poorly by shareholders. Perhaps investors need to rethink their equity positions in this company.
  • T
    Ted
    Why price is up 22.3% today?
  • J
    John
    I see volume is up today. 0.1K and the day is only have over.
  • J
    John
    MPH is over valued by about $1.13
  • T
    Ted
    is there any hope this company will make it to 2020?
  • T
    Ted
    why MPH went up by almost 10% so far today
  • J
    John
    This company should be delisted.